ACIU - AC Immune SA Stock Trading

Shares of the Swiss biotech AC Immune (NASDAQ: ACIU) lost over 42% of their value in pre-market trading Wednesday morning. The biotech's stock is crashing today in response to the news that its experimental Alzheimer's disease (AD) drug semorinemab failed to meet the primary endpoin...

Genentech disclosed that the anti-Tau antibody did not meet the co-primary efficacy endpoint or two secondary endpoints in the TAURIEL study ; the primary safety endpoint was met Multiple other clinical stage programs progressing as planned Investigational new dr...

LAUSANNE, Switzerland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will showcase recent progress in its clinical programs targetin...